Overview

24-hour Efficacy and Tolerability of the Tafluprost-timolol Fixed Association Without Preservatives in Glaucomatous or Ocular Hypertensive Patients Already Treated With Latanoprost Preserved With BAK. A Prospective, Open Study of 3 Months Duration.

Status:
Recruiting

Trial end date:
2022-06-30

Target enrollment:

Participant gender:

Summary

This is a phase IV, interventional, multi-center, open clinical Trial. Patients will be administered one eye drop of tafluprost/timolol fixed combination at 20:00 (+/- 1 hour), in the treatment of open angle glaucoma and ocular hypertension. The patients will suspend the treatment with latanoprost.

Phase:

Phase 4

Details

Lead Sponsor:

Fondazione G.B. Bietti, IRCCS

Treatments:

Timolol